Photodynamic therapy

Skin Cancer Management: A Practical Approach

Volumn , Issue , 2010, Pages 41-56

  Zeitouni, Nathalie C ^a   Oseroff, Allan ^a   Najarian, David J ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892014422     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-88495-0_4     Document Type: Chapter

References (16)

1. Marcus SL, McIntyre WR. Photodynamic Therapy systems and applications. Expert Opin Emerg Drugs. 2002;7:331-334.
2. Tierney EP, Eide MJ, Jacobsen G, Ozog D. Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cosmet Laser Ther. 2008;10:81-86.
3. Kaufmann R, Spelman L, Weightman W, Reifenberger J, Szeimies RM, Verhaeghe E, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinatephotodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008;158:994-999.
4. Surrenti T, De Angelis L, Di Cesare A, Fargnoli MC, Peris K. Efficacy of photodynamic therapy with methyl aminolevulinate in the treatment of superficial and nodular basal cell carcinoma: an open-label trial. Eur J Dermatol. 2007;17:412-415.
5. Levulan Kerastick. FDA Label (NDA 020-965). 2003. http://www.fda.gov/ cder/foi/label/1999/20965lbl.pdf. Last accessed February 3, 2009.
6. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg. 2006;32:1261-1265.
7. METVIXIA (methyl aminolevulinate) Cream, 16.8%. FDA Label. 2007.
8. Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. JDD. 2003;2:629-635.
9. Alexiades-Armenakas M, Geronemus R. Lasermediated photodynamic therapy of actinic cheilitis. J Drugs Dermatol. 2004;3:548-551.
10. Ruiz-Rodriguez R, Sanz-Sanchez T, Cordoba S. Photodynamic Photorejuvenation. Dermatol Surg. 2002;28:742-744.
11. Karrer S, Baumler W, Abels C. Long-Pulse Dye Laser for Photodynamic therapy: Investigations in Vitro and in Vivo. Lasers Surg Med. 1999;25:51-59.
12. Morton C, Campbell S, Gurg G. Intraindividual rightleft comparison of topical methyl aminolaevulinatephotodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006;155:1029-1036.
13. United Kingdom Summary of Product Characteristics. 2007. http://www.medicines.org.uk/. Last accessed 1/20/09.
14. Australia Summary of Product Characteristics. 2007. Australian Regulatory Guidelines for OTC Medicines. http://www.tga.gov. au/docs/html/argom.htm. Last accessed 1/20/09.
15. Horn M, Wolf P, Wulf HC, Warloe T, Fritsch C, Rhodes LE, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003;149:1242-1249.
16. Rhodes LE, deRieMA, Leifsdottir R, Yu RC, Bachmann I, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topicalmethyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143:1131-1136.